InvestSMART

Biotron Limited (ASX:BIT)

ALERT: Price-sensitive ASX Announcement for BIT
Current share price for BIT : $0.002 0 (0%)+
Announcement
Release
21 Jul 2026 10:46AM
Price at Release
$0.002
Full Release
download
Summary
During the quarter ended 30 June 2026, Biotron Limited reported on several financial and operational updates. The company received an R&D Tax Incentive rebate of $525,869 and released 225,151,689 shares from escrow. The Chairman, Michael J. Hoy, retired and Dr. Paul Kasian was appointed as the new Chairman. The company spent $410,000 on research and development and $141,000 on staff costs. Payments to related parties amounted to $141,000. Net cash used in operating activities was $222,000, with cash and cash equivalents at the end of the quarter totaling $1,554,000. Efforts continue on the assessment of their lead anti-HBV candidate BIT-HBV001, and they are engaging with the European Medicines Agency regarding the regulatory pathway for SedRx.
Key Points
  • Received R&D Tax Incentive rebate of $525,869 for 2024/25.
  • 225,151,689 shares issued in December 2025 were released from escrow.
  • Retirement of Chairman Michael J. Hoy and appointment of Dr. Paul Kasian.
  • Expenditure on R&D activities totaled $410,000.
  • Staff costs for the quarter were $141,000.
  • Payments to related parties were $141,000.
  • Net cash used in operating activities was $222,000.
  • Cash and cash equivalents at the end of the quarter were $1,554,000.
  • No proceeds from issue of convertible debt securities.
  • Continued assessment of BIT-HBV001 against Hepatitis Delta Virus.
  • Engagement with EMA for SedRx regulatory pathway.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.